Altered
Antibody Boosts Transplants
A drug that binds to a signaling
molecule in the immune system thwarts transplant rejection in monkeys
given new kidneys or pancreatic tissue.
References:
Kenyon, N.S., et al. In press. Long-term survival and function
of intrahepatic islet allografts in rhesus monkeys treated with humanized
anti-CD154. Proceedings of the National Academy of Sciences.
Kirk, A.D. . . . and D.M. Harlan. 1999. Treatment with humanized
monoclonal antibody against CD154 prevents acute renal allograft rejection
in nonhuman primates. Nature Medicine 5(June):686.
Further Readings:
Alejandro, R., et al. 1997. Long-term function (6 years) of
islet allografts in type 1 diabetes. Diabetes 46(December):1983.
Granstein, R.D. 1996. New strategy for allotransplantation. Lancet
348(Sept. 28):838.
Kirk, A.D., et al. 1997. CTLA4-lg and anti-CD40 ligand prevent
renal allograft rejection in primates. Proceedings of the National
Academy of Sciences 94:8789.
Larsen, C.P., et al. 1996. Long-term acceptance of skin and
cardiac allografts after blocking CD40 and CD28 pathways. Nature
381(May 30):434.
Matzinger, P. 1999. Graft tolerance: A duel of two signals. Nature
Medicine 5(June):616.
Seppa, N. 1997. Two proteins may help transplants. Science News
152(Aug. 9):84.
Sources:
David M. Harlan
Naval Medical Research Center
8901 Wisconsin Avenue
Building 18, Room 232B
Bethesda, MD 20889-5607
Norma S. Kenyon
University of Miami
School of Medicine
Diabetes Research Institute
1450 NW 10th Avenue (R-134)
Miami, FL 33136
Allan D. Kirk
Naval Medical Research Center
Immune Cell Biology Program
8901 Wisconsin Avenue
Bethesda, MD 20889
From Science
News, Vol. 155, No. 24, June 12, 1999, p. 372.
Copyright © 1999, Science Service.
